Filtered by Category: Settlement
Pomerantz recently achieved a $47 million settlement on behalf of defrauded investors in a securities litigation against the American biotechnology company Novavax. The suit revolves around allegedly misleading statements made regarding the development and imminent approval of the company’s Covid-19 vaccine candidate.
Read MoreLast week, Pomerantz moved the court to approve a $97 million settlement in a securities fraud class action against the pharmaceutical company Perrigo Co. plc. The proposed settlement follows a multi-year litigation that included 40 depositions and the review of over half a million documents. Managing Partner Jeremy Lieberman expressed his satisfaction at the result: “We are very proud of our team’s hard-fought accomplishment in bringing this case to a successful resolution after nearly eight years of litigation through a ruling on summary judgment.”
Read MorePomerantz recently achieved a $3 million settlement with the agricultural biotechnology company 22nd Century Group, Inc. The investor suit alleged, among other things, that the company concealed an SEC investigation into its accounting controls.
Read MorePomerantz recently resolved a shareholder litigation against Teva Pharmaceuticals Ltd., in which Pomerantz represented 22 Israeli institutional investors who had opted out of a previous securities class action. The case concerned an alleged price-fixing scheme as well as Teva’s role in the devastating U.S. opioid crisis.
Read MoreIn a significant victory for damaged Deutsche Bank AG investors, the bank has agreed to pay nearly $26.3 million to end a proposed class action against it on behalf of investors who acquired Deutsche Bank stock between March 14, 2017, and May 12, 2020. Pomerantz is sole lead counsel representing the putative class of plaintiffs in the litigation. The recovery represents approximately 49.4% of the likely recoverable damages in this case, which is well above the median recovery of 1.8% of estimated damages for all securities class actions settled in 2021. Plaintiffs have moved the court for approval of the settlement. The complaint, filed in 2020, alleges…
Read MoreOn May 3, 2022, after six years of hard-fought litigation, Pomerantz and co-counsel achieved a significant victory on behalf of consumers by securing a $20 million settlement, pending final approval of the Court, in a consumer class action against Apple, Inc., on behalf of iPhone owners. The motion to settle, filed in U.S. District Court for the Eastern District of New York and unopposed by Apple, would entitle the class members to a recovery of between $15 to $150 per device owned, depending on how many class members file claims. In October 2020, Pomerantz successfully fought to have the Court certify two classes of iPhone users: All individuals and entities…
Read More